Business Wire

ReadSpeaker VoiceLab Powers Sonos Voice Control Custom Voice

17.5.2022 15:00:00 EEST | Business Wire | Press release

Share

ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Sonos, the world’s leading sound experience company, has selected the ReadSpeaker VoiceLab to create a custom voice for Sonos Voice Control, the brand’s voice assistant. Sonos selected VoiceLab, ReadSpeaker’s custom voice production unit, because of the company’s proven experience and expertise in state-of-the-art, AI-driven text-to-speech.

Leading consumer brands are looking to develop their own voice assistants to provide consistently on-brand, personalized and engaged automated customer experiences. Those with a visionary strategy and commitment to consumer privacy, like Sonos, are understanding the broader importance of AI-driven digital voice in helping expand their business and meet consumer needs and expectations, even as they quickly evolve.

The ReadSpeaker VoiceLab managed the development process, including carrying out recordings with Giancarlo Esposito, processing the recorded data, training Deep Neural Networking (DNN) models on that data, and managing quality control, delivery, and all necessary quality assurance steps. Because of the technicality of the voice recordings required to build the custom voice, which requires speech to be delivered in an extremely consistent way that prioritizes precise articulation and style, ReadSpeaker’s VoiceLab experts worked closely with Esposito throughout every stage of the process.

A key challenge in the development of this custom voice was the need for it to comprehend and pronounce non-standard text content that is often found in the music industry. It was also critical that the assistant was able to read artists’ track or album information in numerous languages. The VoiceLab team worked closely with Sonos and Esposito to optimize the speech output for this massively broad domain.

Sonos Voice Control is an entirely new voice experience that delivers fast, accurate hands-free control of your music and your Sonos system with unmatched privacy. Designed with privacy at its core, Sonos Voice Control is the simplest way to control your music, offering complete command of your Sonos system using only your voice. Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available from June 1 in the US and later this year in France on all voice capable Sonos products, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.

“We selected ReadSpeaker to power the custom voice for Sonos Voice Control for a variety of reasons, not least of which was their ability to work closely with us from the development phase all the way through delivery,” said Joseph Dureau, Vice President, Voice Experience, at Sonos. “ReadSpeaker’s approach to custom voice is innovative and extremely thorough – which is exactly what we required for this project – and the company’s dedicated linguistic team has been a critical tool for us throughout this project.”

“As brands become increasingly aware that, much like a visual logo, a custom voice ensures consistently engaging, on-brand interactions across touchpoints, our VoiceLab is developing voices that speak to their brand persona and create unique experiences,” said Roy Lindemann, CMO and CCO EMEA, at ReadSpeaker. “With more consumers leveraging digital voice every day for everything from making purchases to choosing which playlist to listen to, having a custom branded voice is becoming table stakes for delivering a quality, personalized CX in real time. By partnering with Sonos, we are helping to bring yet another brand’s voice to life in an exciting, innovative way.”

Watch the SVC Custom Voice “behind the scenes” video here: https://www.youtube.com/watch?v=vwJ8Ub10arQ

For more information about the ReadSpeaker VoiceLab, visit www.readspeaker.ai/solutions/custom-text-to-speech-tts-voices/.

About ReadSpeaker:
ReadSpeaker is the most trusted independent digital voice partner for global brands, institutions, and organizations. With over 20 years’ experience, ReadSpeaker’s AI-powered text-to-speech solutions and expert assistance enhance the accessibility of digital content and enable more user-friendly and engaging interactions with technology. The company’s flexible cloud and on-premise solutions bring over 110 expressive, humanlike synthetic voices in more than 35 languages to any application or device. The company consistently maintains its uncompromising commitment to data privacy and has so far speech enabled over 10,000 voice applications worldwide.

ReadSpeaker’s digital voice design brand, readspeaker.ai, helps agencies, integrators, and developers to enhance CX and drive sales through consistently engaging, on-brand interactions across touchpoints. For more information, go to readspeaker.ai and follow the company on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ReadSpeaker:
Victoria Newell
V2 Communications for ReadSpeaker
readspeaker@v2comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye